- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Kaya Limited has announced a board meeting to consider the financial results for the quarter and half-year. The company has scheduled its 22nd Annual General Meeting (AGM) through video conferencing to approve audited standalone and consolidated financial statements for FY 2024-25, reappoint Mr. Rishabh Mariwala as director, and appoint M/s. Magia Halwai & Associates as secretarial auditors for five years. Kaya completed the sale of its Middle East subsidiaries during the year, recognizing a gain on sale of discontinued operations of ₹129 Cr and recorded an impairment loss of ₹117 Cr in the prior year related to these subsidiaries. The company reported consolidated revenue of ₹217 Cr, up 5.8%, with a profit of ₹84 Cr, compared to a loss last year, driven by the divestment of Middle East operations. Standalone collections grew 7% to ₹250 Cr, with net revenue up 3% to ₹217 Cr. EBITDA stood at ₹25 Cr (12% margin), down from ₹34 Cr, reflecting investments in brand and central functions. Kaya continues to focus on its India business, investing in clinic upgrades, digital innovation including AI diagnostics, and expanding its product and service portfolio. The company’s net worth remains negative, with current liabilities exceeding current assets by ₹77 Cr, but it continues to receive financial support from promoters and expects to operate as a going concern. The board comprises seven directors with a mix of executive, non-executive, and independent members, including recent appointments effective April 2025. Employee stock option plans remain active with periodic vesting and exercise. No dividend is recommended for FY25. The company maintains robust internal controls and compliance systems, with no reported frauds or material regulatory penalties.